{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-028807","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.640901+00:00","generated_at":"2026-06-24T02:07:24.863474+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AVROBIO reports Q2 2022 net loss of $28.1M, cash runway into Q1 2024","bullets":["Net loss of $28.1M in Q2 2022 vs $31.4M in Q2 2021; R&D expenses $18.9M, down from $22.5M.","Cash and equivalents $132.4M as of June 30, 2022, down from $189.6M at Dec 31, 2021; runway into Q1 2024.","All five patients in Phase 1/2 cystinosis trial remain off oral cysteamine post gene therapy.","FDA Orphan Drug Designation granted for AVR-RD-05 in Hunter syndrome; CTA authorization expected 2H 2022.","Plan to engage with regulators on cystinosis and Gaucher type 3 clinical strategies in 2H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-028807","json":"https://secwatch.observer/filing/0001140361-22-028807.json","markdown":"https://secwatch.observer/filing/0001140361-22-028807.md","text":"https://secwatch.observer/filing/0001140361-22-028807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036122028807/0001140361-22-028807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036122028807/brhc10040479_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:07:24.863474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}